FDA warns 15 companies for selling products containing CBD
The FDA recently issued warning letters to 15 companies for illegally selling products containing cannabidiol, or CBD, according to a press release.
The warning letters state that the companies use product webpages, online stores and social media to market CBD products in interstate commerce; market CBD products as dietary supplements; and/or add CBD to human and animal foods, according to the release.
The FDA has only approved one product containing CBD — Epidiolex (GW Research Ltd.) — for the treatment of seizures in patients aged 2 years and older with Dravet and Lennox-Gastaut syndrome, Amy Abernethy, MD, PhD, FDA principal deputy commissioner, said in the press release.
“We remain concerned that some people wrongly think that the myriad of CBD products on the market, many of which are illegal, have been evaluated by the FDA and determined to be safe, or that trying CBD ‘can’t hurt,’” she added.
The companies that received the warning letters are:
- Apex Hemp Oil LLC of Redmond, Oregon;
- Bella Rose Labs of Brooklyn, New York;
- Daddy Burt LLC doing business as Daddy Burt Hemp Co., of Lexington, Kentucky;
- Healthy Hemp Strategies LLC, doing business as Curapure, of Concord, California;
- Infinite Product Company LLLP, doing business as Infinite CBD, of Lakewood, Colorado;
- Koi CBD LLC of Norwalk, California;
- Natural Native LLC of Norman, Oklahoma;
- Noli Oil of Southlake, Texas;
- Organix Industries Inc., doing business as Plant Organix, of San Bernardino, California;
- Pink Collections Inc. of Beverly Hills, California;
- Private I Salon LLC of Charlotte, North Carolina;
- Red Pill Medical Inc. of Phoenix, Arizona;
- Sabai Ventures Ltd. of Los Angeles;
- Sunflora Inc. of Tampa, Florida/Your CBD Store of Bradenton, Florida; and
- Whole Leaf Organics LLC of Sherman Oaks, California
The companies have 15 working days to show the FDA how they will correct the violations. Their failure to correct the violations “promptly” could result in legal action, including product seizure and/or injunction, the FDA stated.
To help medical professionals learn more about CBD, Healio Primary Care recently published a summary of the Americans for Safe Access’s Guide to CBD.
Disclosure: Abernathy reports no relevant financial disclosures.